The divestitures streamline Charles River's portfolio toward higher-margin businesses. While revenue will decline, the EPS and margin improvements could be positively received by investors focused on profitability. Monitor closing of transactions in Q2 2026 and subsequent margin performance.
Price Chart
Executive Summary
Charles River Laboratories announced the planned divestiture of its CDMO and Cell Solutions businesses to GI Partners for contingent payments, and certain European Discovery Services assets to IQVIA for $145 million in cash plus up to $10 million in additional payments. The company updated its 2026 guidance, expecting the transactions to reduce reported revenue by over $200 million but improve non-GAAP EPS by ~$0.10 and add 100 basis points to non-GAAP operating margin.
Key Facts
- Divesting CDMO and Cell Solutions businesses to GI Partners for future contingent payments; combined 2025 revenue of $143 million
- Divesting European Discovery Services assets to IQVIA for $145 million cash plus up to $10 million in additional payments; 2025 revenue of $144 million
- Both transactions expected to close in Q2 2026
- Planned divestitures to reduce 2026 reported revenue by slightly more than $200 million
- Expected to generate at least 100 basis points of incremental non-GAAP operating margin improvement in 2026
- Expected to add approximately $0.10 to non-GAAP EPS for the partial year
Financial Impact
Revenue reduction of >$200 million in 2026, $0.10 accretion to non-GAAP EPS, 100 bps improvement in non-GAAP operating margin
Risk Factors
- Failure to complete either divestiture transaction as planned
- Potential for higher-than-expected divestiture-related costs that could reduce the non-GAAP EPS benefit
- Loss of revenue streams could impact growth metrics despite margin improvements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-011395 |
| Document: 0001628280-26-011395-index-headers.html | 0001628280-26-011395 |
| Document: 0001628280-26-011395-index.html | 0001628280-26-011395 |
| Document: 0001628280-26-011395.txt | 0001628280-26-011395 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Cluster | $296.41 $294.44 | ▼ −0.66% | ▼ −0.16% | $290.19 (−2.10%) |
Aug 20, 2026 6w ago | Insider Cluster | $291.45 $278.06 | ▼ −4.59% | ▼ −4.59% | $290.19 (−0.43%) |
Aug 13, 2026 7w ago | Insider Cluster | $281.27 $278.26 | ▼ −1.07% | ▲ +0.68% | $290.19 (+3.17%) |
Aug 11, 2026 7w ago | Insider Cluster | $282.00 $278.35 | ▼ −1.29% | ▼ −0.24% | $290.19 (+2.90%) |
Aug 10, 2026 7w ago | Insider Cluster | $282.00 $278.35 | ▼ −1.29% | ▼ −0.24% | $290.19 (+2.90%) |
Aug 5, 2026 8w ago | 8-K | $260.72 $291.76 | ▲ +11.91% | ▲ +12.51% | $290.19 (+11.30%) |
May 7, 2026 21w ago | 8-K | $180.78 $179.87 | ▲ +0.51% | ▲ +3.64% | $290.19 (−60.52%) |
Feb 25, 2026 31w ago | 8-K | $167.50 $164.89 | ▼ −1.56% | ▲ +3.68% | $290.19 (+73.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access